NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Wed, 7 May · 19:57 IST

Completion of tenure of an Independent Director

Management Changes View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Neuland Laboratories has informed the stock exchanges that Dr. Nirmala Murthy (DIN: 00734866) has completed her second term as an Independent Director and stepped down from the board effective May 7, 2025. This is a routine end-of-tenure event, not a mid-term resignation. No reasons for concern or governance issues have been disclosed. The company will need to appoint a replacement independent director to fill the vacancy on its board.

Likely market impact

This is a routine governance change with no material impact on the company's operations or financials. Investors should watch for the appointment of a new independent director to ensure the board remains compliant with composition requirements.